Topical Minoxidil for Hair Loss

Topical minoxidil is one of the most extensively studied medical treatments for androgenetic alopecia and remains the only topical medication currently FDA approved in the United States for pattern hair loss in both men and women.

It is available without a prescription in several formulations, most commonly 2 percent solution, 5 percent solution and 5 percent foam.

Minoxidil does not lower dihydrotestosterone, or DHT, and does not directly interfere with the androgen driven process responsible for androgenetic alopecia. Instead, it acts as a hair growth stimulant, helping susceptible follicles remain in or return to the active growth phase and, in some patients, increasing the size and productivity of miniaturized follicles.

This distinction is important.

Minoxidil can improve hair growth and help maintain coverage, but it does not remove the underlying genetic sensitivity of the follicle to androgens.

For many patients, particularly men with progressive androgenetic alopecia, minoxidil may therefore be used together with a treatment that addresses the androgen component of hair loss.

Topical minoxidil has been used for decades and has a generally favorable safety profile when used correctly. Its major limitations are variable individual response, the inconvenience of regular scalp application and the need for continued treatment to maintain treatment dependent benefit.

Topical Minoxidil Is Not Loniten

Minoxidil exists in both topical and oral forms.

Loniten is a brand name for oral minoxidil tablets, originally developed as a powerful prescription medication for severe hypertension.

Rogaine is the best known brand associated with topical minoxidil for hair loss.

The active drug is minoxidil in both cases, but oral and topical minoxidil create very different levels of systemic exposure and have different dosing and safety considerations.

Low dose oral minoxidil for hair loss is discussed separately in the AHLA’s Low Dose Oral Minoxidil guide.

How Topical Minoxidil Was Discovered

Minoxidil was originally developed as an oral vasodilator for the treatment of severe high blood pressure.

Physicians noticed that some patients taking oral minoxidil developed substantial hair growth, including increased facial and body hair.

That observation eventually led researchers to investigate whether minoxidil applied directly to the scalp could stimulate scalp hair growth without exposing patients to the much larger systemic doses used for hypertension.

Rogaine 2 percent topical minoxidil was approved in the United States as a prescription treatment for male pattern hair loss in 1988.

Topical minoxidil subsequently became available for women, and in 1996 the 2 percent formulations became available without a prescription.

The FDA approved 5 percent topical minoxidil solution for men in 1997.

Foam formulations were developed later, including 5 percent foam for men and once daily 5 percent foam for women.

Minoxidil has therefore accumulated decades of clinical use and remains one of the foundational treatments for pattern hair loss.

How Does Minoxidil Work?

The exact mechanism by which minoxidil stimulates hair growth is still not completely understood.

Describing minoxidil simply as a drug that “increases blood circulation to the scalp” is an oversimplification.

Minoxidil appears to influence several aspects of follicular biology.

It can shorten the resting, or telogen, phase of the hair cycle and encourage follicles to enter the active anagen growth phase.

It may prolong anagen, increase follicular size and improve the production of thicker terminal hairs in follicles that remain capable of responding.

Experimental evidence has also implicated potassium channel activity, vascular endothelial growth factor, or VEGF, and signaling pathways involved in follicular growth.

Importantly, minoxidil itself is a prodrug.

It must be converted into its active metabolite, minoxidil sulfate, by sulfotransferase enzymes within the hair follicle.

That conversion appears to be one important reason why some people respond extremely well to topical minoxidil while others show little visible benefit.

Why Does Minoxidil Work Better for Some People Than Others?

Response to topical minoxidil varies considerably.

One important factor is the activity of the enzyme SULT1A1, a sulfotransferase present within the outer root sheath of the hair follicle.

This enzyme converts minoxidil into active minoxidil sulfate.

Sulfotransferase activity varies among individuals. Someone with relatively high follicular enzyme activity may activate topical minoxidil efficiently, while another person may convert considerably less of the drug.

Other factors also affect response.

The diagnosis needs to be correct. The follicles must still be viable. Treatment needs to reach the scalp consistently. The degree and duration of follicular miniaturization matter. Scalp inflammation or dermatitis can interfere with treatment, and irregular application can make an effective drug appear ineffective.

Tests intended to estimate follicular sulfotransferase activity have been investigated as predictors of topical minoxidil response, but they are not part of a universally established standard of care.

Does Topical Minoxidil Actually Work?

Yes.

Topical minoxidil has extensive randomized clinical trial evidence demonstrating that it can increase hair growth in both men and women with androgenetic alopecia.

The degree of response varies substantially.

Some patients experience obvious cosmetic improvement.

Others primarily maintain hair that might otherwise have continued to miniaturize.

Some experience only modest improvement.

And some appear to obtain little meaningful benefit.

This variability is why minoxidil should not be described either as a miracle hair growth treatment or as a marginal treatment that rarely works.

It is an effective medication with highly variable individual response.

Is 5 Percent Minoxidil Better Than 2 Percent for Men?

On average, yes.

A major randomized controlled trial followed 393 men with androgenetic alopecia for 48 weeks and compared 5 percent minoxidil solution, 2 percent minoxidil solution and placebo.

Both minoxidil concentrations outperformed placebo.

The 5 percent formulation produced an earlier response and significantly greater hair growth than the 2 percent formulation.

At 48 weeks, the investigators reported approximately 45 percent greater hair regrowth with 5 percent minoxidil than with 2 percent minoxidil.

The tradeoff was somewhat more itching and local scalp irritation with the stronger formulation.

For this reason, 5 percent topical minoxidil has become the most commonly used topical strength for men.

What About Women?

Topical minoxidil is also FDA approved for female pattern hair loss.

Women have several established topical options.

Two percent minoxidil solution is traditionally used twice daily.

Five percent minoxidil foam is FDA approved for women once daily.

In a large randomized study involving 381 women, both 2 percent and 5 percent minoxidil solutions produced greater hair growth than placebo after 48 weeks. The 5 percent formulation produced stronger results on several measures but was also associated with more local irritation and unwanted facial hair growth.

Additional randomized trials established that once daily 5 percent foam is effective for female pattern hair loss.

One Phase III placebo controlled study involving more than 400 women demonstrated significant improvement in hair counts and scalp coverage after 24 weeks.

The availability of once daily 5 percent foam has become particularly useful for women who find twice daily liquid application difficult or who develop irritation from solution based products.

Is Minoxidil Foam Better Than Minoxidil Solution?

Neither formulation is universally better.

They have practical differences.

Traditional minoxidil solution generally contains alcohol, water and propylene glycol. Propylene glycol helps dissolve minoxidil but can contribute to itching, scaling and irritation in some patients.

Minoxidil foam does not require propylene glycol and is often better tolerated by people with sensitive scalps.

Foam also tends to dry more quickly and may be cosmetically easier for some patients.

On the other hand, some people with longer or denser hair find liquid solution easier to place precisely onto the scalp, and generic solution is often inexpensive.

The best formulation is usually the one that delivers an effective dose to the scalp and can be used consistently without unacceptable irritation.

Is Propylene Glycol Usually the Cause of Minoxidil Allergy?

Not always.

For years, scalp reactions to minoxidil solution were commonly blamed on propylene glycol.

Propylene glycol can certainly cause irritant or allergic contact dermatitis.

However, more recent evidence shows that minoxidil itself can also be an allergen.

A 2025 systematic review of 99 patients with patch test confirmed allergic contact dermatitis associated with topical minoxidil found that minoxidil itself was identified as the primary allergen in approximately 75 percent of cases, while propylene glycol accounted for approximately 17 percent.

This matters clinically.

Someone who reacts to propylene glycol may tolerate a propylene glycol free foam.

Someone who is truly allergic to minoxidil itself may react to minoxidil regardless of the vehicle.

Persistent itching, redness, scaling or dermatitis deserves proper evaluation rather than simply assuming that every reaction is caused by the solvent.

How Is Topical Minoxidil Used?

The medication needs to reach the scalp, not simply coat the hair.

For men using FDA labeled 5 percent foam, the standard direction is approximately half a capful applied to the affected scalp twice daily.

For standard 5 percent or 2 percent liquid solution, the usual labeled amount is 1 mL twice daily.

For women using FDA labeled 5 percent foam, the standard regimen is approximately half a capful once daily.

Specific products can have different instructions, so the label for the actual formulation should be followed.

Using more medication or applying it more frequently than directed has not been shown to produce better results and may increase irritation or systemic exposure.

Should Minoxidil Be Applied to Wet or Dry Hair?

Topical minoxidil is generally intended to be applied to a dry scalp.

It is not necessary to shampoo immediately before every application.

If the hair has been washed, the scalp should generally be allowed to dry before applying minoxidil.

The hair should be parted so that the product reaches the skin rather than being absorbed mostly by the hair shafts.

Hands should be washed after application.

How Long Should Minoxidil Stay on the Scalp?

Current product instructions generally recommend allowing topical minoxidil to remain on the scalp for approximately four hours before washing or thoroughly wetting the scalp.

The medication should also be allowed to dry before wearing a hat or lying on a pillow.

Depending on the formulation and amount applied, complete drying may take approximately two to four hours.

This is particularly important when minoxidil is applied at night because wet medication can transfer onto the face, pillow, another person or a pet.

How Long Does Topical Minoxidil Take to Work?

Hair growth is slow.

Some men may begin noticing changes after approximately two months of consistent 5 percent use, but many require at least four months.

For women and for patients with more subtle changes, meaningful assessment often requires longer.

In clinical practice, four to six months is generally a reasonable minimum period before deciding whether topical minoxidil is providing benefit, and six to twelve months may provide a better picture of the cosmetic response.

Objective photographs taken under consistent lighting and measurements of hair density or miniaturization can be far more useful than daily mirror inspection.

Can Minoxidil Cause Shedding When Treatment Begins?

Yes.

A temporary increase in shedding can occur after topical minoxidil is started.

Minoxidil can accelerate the transition of resting telogen follicles into a new growth cycle. Older hairs may therefore be released as follicles begin cycling.

A 2025 study specifically tracking shedding in patients using topical 2 percent or 5 percent minoxidil documented a temporary increase in shedding during the first 12 weeks of treatment.

Not everyone experiences a noticeable shed.

A shed is also not required for minoxidil to work.

Temporary early shedding does not necessarily mean that the medication is making androgenetic alopecia worse.

However, severe shedding, shedding that continues well beyond the expected early period or a major change in the pattern of hair loss should not automatically be blamed on minoxidil. Other causes of hair loss should be considered.

Does More Shedding Mean Minoxidil Will Work Better?

Not necessarily.

The 2025 shedding study found an association between the magnitude of early shedding and some measures of later improvement among patients using 5 percent minoxidil.

That is interesting, but it should not be converted into a rule that a dramatic shed predicts a dramatic response.

Some excellent responders experience little noticeable shedding.

Some patients who shed ultimately have limited improvement.

The absence of shedding is not evidence that minoxidil is failing.

Does Minoxidil Work on the Hairline and Frontal Scalp?

Yes, it can.

This is an area where FDA product labeling can be confusing.

Many men’s minoxidil labels state that the product is intended for hair loss on the top or vertex of the scalp and is not intended for frontal baldness or a receding hairline.

That wording largely reflects the areas and patterns evaluated in the original registration studies.

Subsequent clinical research has specifically studied frontotemporal hair loss.

A randomized placebo controlled trial of 5 percent minoxidil foam found improvement in hair width and perceived scalp coverage in both the frontotemporal and vertex regions.

A follow up study extending treatment to 104 weeks found that continued 5 percent foam helped stabilize hair density, hair width and scalp coverage in both areas.

So it is inaccurate to say that minoxidil biologically works only in the crown.

What minoxidil cannot reliably do is recreate a deeply recessed juvenile hairline after follicles have undergone advanced miniaturization.

Improving or preserving miniaturizing frontal hair is very different from rebuilding hair that has already been lost.

Does Minoxidil Stop DHT?

No.

Minoxidil is not an antiandrogen and does not meaningfully block the conversion of testosterone to DHT.

This is one of the most important distinctions between minoxidil and medications such as finasteride or dutasteride.

Minoxidil stimulates follicular growth.

Finasteride and dutasteride address an important hormonal mechanism driving androgenetic alopecia.

For some men, using the treatments together can therefore address two different aspects of the condition.

Minoxidil should not be described as replacing antiandrogen treatment simply because it produces visible growth.

Can Minoxidil Be Combined With Finasteride?

Yes.

Topical minoxidil and finasteride are commonly used together because they work through different mechanisms.

Randomized studies of topical combinations have demonstrated that adding finasteride to minoxidil can produce greater improvement than minoxidil alone in some men.

The medications can be used separately or, in some cases, combined into one topical formulation.

A fixed combination may improve convenience but reduces flexibility because the dose of one drug cannot easily be changed without changing the other.

The appropriate regimen depends on diagnosis, treatment response, tolerance and long term planning.

Topical Minoxidil Versus Oral Minoxidil

Low dose oral minoxidil has become increasingly common as an off label hair loss treatment.

Recent randomized trials and meta analyses comparing oral with topical minoxidil have generally found similar average improvements in hair density and hair diameter, although the studies remain relatively short and involve modest numbers of patients.

The treatments have different advantages and disadvantages.

Topical minoxidil has decades of use, is FDA approved for pattern hair loss and generally creates much lower systemic exposure.

Its limitations include scalp irritation, cosmetic inconvenience and adherence.

Oral minoxidil avoids daily scalp application and can work in some people who respond poorly to topical therapy, but it exposes the entire body to the medication and carries systemic considerations including hypertrichosis, fluid retention, blood pressure effects and changes in heart rate.

Oral minoxidil for hair loss is not FDA approved and is discussed separately in the AHLA’s Low Dose Oral Minoxidil guide.

What Are the Most Common Side Effects of Topical Minoxidil?

Most adverse effects are local.

They can include itching, dryness, redness, scaling, flaking, burning and contact dermatitis.

Some people experience changes in hair texture or color.

Unwanted facial or body hair growth can also occur.

This may result from medication transferring from the scalp onto other skin, from medication on the hands or pillow, or from small amounts of minoxidil entering the systemic circulation.

Women appear particularly susceptible to cosmetically noticeable facial hypertrichosis.

Careful scalp application, washing the hands afterward and allowing the product to dry before going to bed can reduce unintended transfer.

Can Topical Minoxidil Affect Blood Pressure or the Heart?

Systemic cardiovascular effects from correctly used topical minoxidil are uncommon, but they are possible.

Minoxidil was originally developed as a powerful systemic vasodilator.

Only a small proportion of properly applied topical medication normally reaches the systemic circulation, which is why topical treatment generally does not produce the cardiovascular effects associated with antihypertensive oral doses.

Nevertheless, current FDA regulated topical minoxidil labels instruct patients with heart disease to consult a physician before use.

Treatment should be stopped and medical evaluation sought if symptoms such as chest pain, rapid heartbeat, faintness, significant dizziness, unexplained rapid weight gain or swelling of the hands or feet occur.

Applying excessive amounts, using minoxidil on damaged or inflamed skin or applying it to areas other than the scalp can potentially alter exposure.

Does Topical Minoxidil Cause Sexual Side Effects?

Sexual dysfunction is not an established adverse effect of topical minoxidil.

Minoxidil does not lower DHT, suppress testosterone or act as an antiandrogen.

Controlled clinical trials and FDA topical labeling have not identified erectile dysfunction, decreased libido or ejaculation disorders as characteristic adverse effects of topical minoxidil.

That does not mean every symptom occurring during treatment should automatically be dismissed.

It means that, unlike finasteride and dutasteride, there is not an established pharmacologic or clinical association between topical minoxidil and sexual dysfunction.

A patient developing a new sexual symptom should consider other medications, health conditions and possible causes rather than automatically assuming topical minoxidil is responsible.

Can Topical Minoxidil Cause Unwanted Facial Hair?

Yes.

Unwanted facial hair is a known adverse effect, particularly in women.

It can occur when medication is transferred onto the forehead, cheeks or other facial skin.

Low level systemic absorption may also contribute in some patients.

Applying the product precisely to the scalp, washing the hands immediately after application and allowing the treatment to dry completely before lying down can reduce the risk.

If unwanted facial hair develops because of minoxidil, it generally diminishes after the exposure is stopped, although this can take time.

What Happens if Minoxidil Is Stopped?

The benefits of minoxidil are treatment dependent.

Minoxidil does not permanently cure androgenetic alopecia.

If treatment is effective and then discontinued, the follicles gradually lose the stimulation being provided by the medication and the underlying hair loss process resumes.

FDA regulated product information states that newly regrown hair is generally lost within approximately three to four months after treatment is discontinued.

This should not be interpreted as minoxidil somehow damaging the hair or making the person dependent on the drug.

The medication was supporting hair that the underlying condition would otherwise have allowed to miniaturize or shed.

When the treatment is removed, that support is removed.

Does Minoxidil Make Hair Loss Worse in the Long Run?

There is no evidence that appropriately used topical minoxidil accelerates androgenetic alopecia.

This misconception often results from two observations.

First, some patients experience temporary shedding when treatment begins.

Second, patients who stop a successful treatment can lose the hair that was being maintained by minoxidil, sometimes within several months.

That return toward the untreated course of hair loss can make it appear that minoxidil made the condition worse.

It did not create the underlying androgenetic alopecia.

Can Minoxidil Stop Working After Several Years?

Hair loss can continue to evolve even while treatment remains effective.

Androgenetic alopecia is progressive.

A patient may initially gain hair or substantially improve density and then, years later, notice gradual thinning despite continued minoxidil use.

That does not necessarily mean the drug suddenly stopped working.

Minoxidil may still be providing benefit while the underlying disease gradually progresses.

Long term studies of 5 percent foam have demonstrated stabilization of measurable hair characteristics over approximately two years in some patients, even when dramatic early improvement did not continue indefinitely.

Maintenance can itself represent a meaningful treatment effect.

Can Topical Minoxidil Be Used for Other Types of Hair Loss?

Yes, but the evidence varies considerably depending on the diagnosis.

Topical minoxidil is sometimes used off label as a supportive growth treatment in conditions such as chronic telogen effluvium, early traction alopecia, alopecia areata, chemotherapy associated hair loss and some scarring alopecias.

It is important to understand what minoxidil can and cannot do in these conditions.

Minoxidil does not treat autoimmune inflammation in alopecia areata.

It does not treat the inflammatory process responsible for scarring alopecia.

It cannot regenerate a follicle that has already been permanently destroyed by scar formation.

In these situations, minoxidil may sometimes improve the performance of surviving follicles, but the underlying disease still needs to be diagnosed and treated appropriately.

Topical Minoxidil and Microneedling

Microneedling has been studied as an adjunct to topical minoxidil, and several small randomized trials have reported greater average improvement in hair counts when the two are combined than with topical minoxidil alone.

However, the evidence has important limitations.

Most studies have involved relatively small numbers of patients, short treatment periods and widely different microneedling protocols. Needle depths, treatment frequency, devices and endpoints vary considerably among studies, making it difficult to establish an optimal or standardized protocol.

Microneedling also intentionally disrupts the skin barrier.

This is particularly important when it is combined with topical minoxidil.

Many conventional minoxidil solutions contain significant concentrations of alcohol, including denatured or SD alcohol, as well as propylene glycol. These ingredients can be irritating even when applied to intact skin.

Applying an alcohol based minoxidil solution immediately onto freshly microneedled scalp can produce substantial stinging and irritation and may increase inflammation.

More importantly, creating channels through the epidermal barrier can increase drug penetration. That means the amount of minoxidil reaching deeper tissue and potentially the systemic circulation may no longer resemble the exposure produced by ordinary application to intact scalp.

For that reason, results from standard topical minoxidil studies cannot simply be applied to minoxidil used immediately after microneedling.

Some published clinical protocols have specifically withheld minoxidil for approximately 24 hours after microneedling, rather than applying it directly onto freshly treated skin.

The American Hair Loss Association does not recommend routine microneedling as an adjunct to topical minoxidil, particularly home microneedling followed by immediate application of an alcohol based minoxidil solution.

Potential concerns include unnecessary inflammation, irritation, infection, altered drug absorption and injury from aggressive or poorly controlled treatment.

The fact that a procedure may increase penetration does not automatically make it safer or more effective over the long term.

More penetration is not necessarily better.

Until larger, standardized studies establish the optimal depth, frequency, timing and long term safety of microneedling with topical minoxidil, the AHLA believes patients are better served by using established medical treatments in a controlled and evidence based manner.

Can Minoxidil Be Used After Hair Transplant Surgery?

Minoxidil is sometimes incorporated into medical therapy before or after hair transplant surgery to support native miniaturizing hair.

It does not make transplanted follicles permanent and does not replace proper surgical planning.

The primary long term concern after a transplant remains the continued progression of the patient’s untreated native androgenetic alopecia.

Timing around surgery should be directed by the treating physician or surgeon because applying topical products to newly transplanted or healing skin too early can cause unnecessary irritation.

Can Children Use Topical Minoxidil?

FDA regulated over the counter topical minoxidil products are intended for adults 18 years of age and older.

Minoxidil is sometimes used by specialists for selected pediatric hair disorders, but that is off label and requires appropriate medical supervision.

It should not be casually used on children simply because it is available without a prescription.

Topical Minoxidil During Pregnancy and Breastfeeding

The American Hair Loss Association does not recommend routine topical minoxidil use during pregnancy.

Current over the counter labeling warns that minoxidil may be harmful if used during pregnancy or breastfeeding.

Breastfeeding is somewhat more nuanced.

The National Library of Medicine’s LactMed review states that topical minoxidil is considered acceptable once breastfeeding is established, but emphasizes that an infant should not come into contact with treated skin because minoxidil can be absorbed and cause adverse effects such as excessive hair growth.

A woman who is pregnant, attempting conception or breastfeeding should discuss minoxidil use with her physician rather than simply assuming that topical treatment creates no systemic or infant exposure.

Minoxidil Can Be Dangerous to Pets

This is an important safety issue that has historically received far too little attention.

Minoxidil can be highly toxic to cats and dogs, particularly cats.

Pets have become seriously ill after licking a treated scalp, contacting a contaminated pillowcase, being splashed during application or finding minoxidil containers or discarded materials.

Even relatively small exposures can be dangerous.

A review of reported dog and cat exposures found clinically significant toxicity after very small exposures, including drops and licks.

More recent dermatology literature has renewed attention to this risk.

Anyone using topical minoxidil around pets should store the product securely, clean spills immediately, wash hands after application, dispose of contaminated tissues or applicators safely and prevent pets from licking or rubbing against the treated scalp or contaminated bedding.

A suspected pet exposure warrants immediate veterinary or animal poison control advice.

What Should Someone Know Before Starting Topical Minoxidil?

The most important step is making sure the diagnosis is correct.

Sudden hair loss, patchy hair loss, significant scalp inflammation, pain, pustules, scarring or unexplained diffuse shedding should not simply be treated as androgenetic alopecia because minoxidil is available over the counter.

Someone using topical minoxidil should understand what concentration and formulation is being used, how often it should be applied, how much should be applied, where on the scalp it should be placed and how response will be measured.

The patient should also understand that more product is not necessarily better, temporary early shedding can occur, meaningful improvement takes months and treatment dependent benefit generally requires continued use.

The AHLA Perspective

Topical minoxidil has sometimes been dismissed because it does not address DHT and because not everyone experiences dramatic regrowth.

That understates the value of the medication.

Topical minoxidil has decades of randomized clinical evidence, FDA approval for pattern hair loss in both men and women and a generally favorable safety profile when used appropriately.

Five percent minoxidil has demonstrated greater average efficacy than 2 percent treatment in men, and effective FDA approved formulations are available for women.

It also has limitations.

Response varies greatly among individuals. Some patients obtain substantial improvement while others gain very little. Daily application can become inconvenient. Solution based products can irritate the scalp. Treatment dependent gains require continued therapy.

Most importantly, minoxidil does not treat the androgen mechanism driving androgenetic alopecia.

For someone with progressive hair loss, visible growth from minoxidil should not create the false impression that the underlying androgen driven miniaturization process has necessarily been controlled.

At the same time, it is equally inaccurate to dismiss minoxidil as merely a weak or temporary cosmetic treatment.

For the right patient, a good response can provide meaningful improvement and years of additional hair preservation.

The appropriate question is not whether minoxidil “works.”

The question is how well it works for the individual patient, whether the treatment is sustainable and how it fits into a rational long term plan for the underlying cause of the hair loss.

Used for: Male Pattern Baldness, Female Pattern Baldness

Selected References

1. Olsen EA, Dunlap FE, Funicella T, et al. A Randomized Clinical Trial of 5% Topical Minoxidil Versus 2% Topical Minoxidil and Placebo in the Treatment of Androgenetic Alopecia in Men. Journal of the American Academy of Dermatology. 2002;47:377 to 385. doi:10.1067/mjd.2002.124088. PubMed
2. Lucky AW, Piacquadio DJ, Ditre CM, et al. A Randomized, Placebo Controlled Trial of 5% and 2% Topical Minoxidil Solutions in the Treatment of Female Pattern Hair Loss. Journal of the American Academy of Dermatology. 2004;50:541 to 553. PubMed
3. Blume Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia Bartels N. A Randomized, Single Blind Trial of 5% Minoxidil Foam Once Daily Versus 2% Minoxidil Solution Twice Daily in the Treatment of Androgenetic Alopecia in Women. Journal of the American Academy of Dermatology. 2011;65:1126 to 1134.e2. doi:10.1016/j.jaad.2010.09.724. PubMed
4. Bergfeld W, Washenik K, Callender V, et al. A Phase III, Multicenter, Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam Versus Vehicle in Women With Female Pattern Hair Loss.Journal of Drugs in Dermatology. 2016;15:874 to 881. PubMed
5. Blume Peytavi U, Shapiro J, Messenger AG, et al. Efficacy and Safety of Once Daily Minoxidil Foam 5% Versus Twice Daily Minoxidil Solution 2% in Female Pattern Hair Loss: A Phase III Randomized Investigator Blinded Study. Journal of Drugs in Dermatology. 2016;15:883 to 889. PubMed
6. Kanti V, Messenger A, Dobos G, et al. A Single Centre, Randomized, Double Blind, Placebo Controlled Clinical Trial to Investigate the Efficacy and Safety of Minoxidil Topical Foam in Frontotemporal and Vertex Androgenetic Alopecia in Men. Skin Pharmacology and Physiology. 2015;28:236 to 244. doi:10.1159/000375320. PubMed
7. Kanti V, Hillmann K, Kottner J, Stroux A, Canfield D, Blume Peytavi U. Effect of Minoxidil Topical Foam on Frontotemporal and Vertex Androgenetic Alopecia in Men: A 104 Week Open Label Clinical Trial. Journal of the European Academy of Dermatology and Venereology. 2016;30:1183 to 1189. doi:10.1111/jdv.13324. PubMed
8. Messenger AG, Rundegren J. Minoxidil: Mechanisms of Action on Hair Growth. British Journal of Dermatology. 2004;150:186 to 194. doi:10.1111/j.1365-2133.2004.05785.x. PubMed
9. Pietrauszka K, Bergler Czop B. Sulfotransferase SULT1A1 Activity in Hair Follicle, a Prognostic Marker of Response to Minoxidil Treatment in Patients With Androgenetic Alopecia: A Review. Postępy Dermatologii i Alergologii. 2022;39:472 to 478. doi:10.5114/ada.2020.99947. PubMed
10. Whether the Transient Hair Shedding Phase Exists After Minoxidil Treatment and Whether It Predicts Treatment Efficacy: A Retrospective Study in Androgenetic Alopecia Patients. 2025. PubMed
11. Kiratiwongwan R, Boonchai W, Kanokrungsee S. Allergic Contact Dermatitis to Topical Preparations Containing Minoxidil: A Systematic Review and Individual Participant Data Meta Analysis. Dermatitis.2025;36:200 to 206. doi:10.1089/derm.2024.0092. PubMed
12. Olsen EA, et al. Summation and Recommendations for the Safe and Effective Use of Topical and Oral Minoxidil. Journal of the American Academy of Dermatology. 2025;93:457 to 465. doi:10.1016/j.jaad.2025.04.016. PubMed
13. Sobral MVS, Moreira JLM, Rodrigues LK, et al. Efficacy and Safety of Oral Minoxidil Versus Topical Solution in Androgenetic Alopecia: A Meta Analysis of Randomized Clinical Trials. International Journal of Dermatology. 2025;64:479 to 484. doi:10.1111/ijd.17524. PubMed
14. Dias FR, Yong SS, FitzGerald H, Sinclair RD, Bhoyrul B. Expanding the Therapeutic Landscape of Minoxidil for Androgenetic Alopecia: Topical, Oral and Sublingual Formulations. Frontiers in Pharmacology.2026;16:1718208. doi:10.3389/fphar.2025.1718208. PubMed
15. U.S. National Library of Medicine. Minoxidil Topical Aerosol 5% for Men: Drug Facts and Consumer Information. DailyMed
16. U.S. National Library of Medicine. Minoxidil Topical Aerosol 5% for Women: Drug Facts and Consumer Information. DailyMed
17. U.S. National Library of Medicine. Minoxidil Topical Solution 2% for Women: Drug Facts and Consumer Information. DailyMed
18. National Library of Medicine. Minoxidil. Drugs and Lactation Database, LactMed. Updated May 15, 2026. LactMed
19. Ahmed KMA, Kozaa YA, Abuawwad MT, et al. Evaluating the Efficacy and Safety of Combined Microneedling Therapy Versus Topical Minoxidil in Androgenetic Alopecia: A Systematic Review and Meta Analysis. Archives of Dermatological Research. 2025;317:528. doi:10.1007/s00403-025-04032-1. PubMed
20. Fertig RM, Gamret AC, Cervantes J, Tosti A. Microneedling for the Treatment of Hair Loss? Journal of the European Academy of Dermatology and Venereology. Review of the evidence, limitations and need for standardized protocols. PubMed
21. Randomized Clinical Study of Microneedling Combined With Minoxidil in Androgenetic Alopecia. Includes a protocol withholding topical minoxidil for approximately 24 hours after microneedling. Full Text
22. McMullen E, Xiong G, Rayner DG, et al. Minoxidil Toxicosis in Cats and Dogs: A Scoping Review and Call to Action. Journal of the American Academy of Dermatology. 2025;93:522 to 524. doi:10.1016/j.jaad.2025.04.006. PubMed